Core Insights - Glaukos Corporation, an ophthalmic device maker focused on glaucoma solutions, reported a significant insider sale by director Marc Stapley, who sold 15,000 shares for approximately $1.9 million after a challenging year for the stock [1][6]. Company Overview - Glaukos Corporation specializes in ophthalmic medical devices and pharmaceutical therapies, particularly for glaucoma and related eye conditions, serving ophthalmologists and healthcare institutions both domestically and internationally [5]. - The company has a market capitalization of $6.85 billion and reported a revenue of $469.82 million with a net income of -$87.61 million for the trailing twelve months (TTM) [4]. Transaction Details - The transaction involved the sale of 15,000 shares at a value of $1.92 million, with post-transaction direct ownership reduced to 37,449 shares valued at approximately $4.71 million [2][7]. - This sale is significantly larger than Stapley's median administrative disposition of 6,250 shares since May 2024, indicating a notable change in his holdings [7]. Recent Developments - On January 28, 2026, Glaukos received FDA approval for the re-administration of one of its supplements for glaucoma patients, allowing physicians to administer the supplement multiple times based on corneal conditions, which may positively impact the company's market position [6]. - Despite a rough year in 2025 with a stock decline of approximately 25%, Glaukos' stock has seen a 4.3% increase in January 2026, potentially aided by the recent FDA approval [9]. Ownership Implications - Following the recent transaction, Stapley's direct holdings represent 0.07% of outstanding shares, with no options outstanding, indicating a reduced capacity for future transactions [7]. - The transactions were conducted under a Rule 10b5-1 trading plan, allowing for pre-scheduled sales by insiders [8].